InvestorsHub Logo
Followers 121
Posts 2016
Boards Moderated 0
Alias Born 11/20/2012

Re: Blue Fin post# 303557

Saturday, 06/20/2020 11:00:11 AM

Saturday, June 20, 2020 11:00:11 AM

Post# of 403599
here is a copy of my email to Charles Triano at Pfizer head of drug research and development

Dear Charles:

I have been a long term investor in Pfizer for many years and I am happy to share with you a report regarding a special drug called Brilacidin developed by Innovative Pharmaceuticals, a small biotech company from Massachusetts has had wonderful success testing a Brilacidin as a therapeutic agent for battling COVID-19.

Two independent RBL labs ( US Regional Biocontainment laboratories ) have verified superior efficacy when using Brilacidin in vitro against COVID-19 virus.
Approximately two weeks ago, one independent lab which have been designated by BARDA to test many novel drugs and the Covid task force set up by President Trump reported that when Brilacidin was exposed to VERO monkey renal cells for one hour then exposed to the Covid 19 virus there was a 75% reduction in infection load. Two independent RBL confirmed the data. https://finance.yahoo.com/news/innovation-pharmaceuticals-brilacidin-reduces-viral-113010146.html

This past week new data came back from the same RBL’s involved with testing for Brilacidin use against Covid 19 in VERO monkey pneumocytes and it showed 95% and 97% reduction in viral load of infection of lung tissues with prior pretreatment with Brilacidin. The p value for the tests was an astonishing (p< .0001) and both labs reported data that was not only promising but outstanding, Covid 19 kills by attaching to and infecting both. https://finance.yahoo.com/news/innovation-pharmaceuticals-brilacidin-inhibits-sars-113010429.html

Brilacidin has already been used safely in three separate human trials, ABSSI, oral mucositis, and for inflammatory bowel disease and has shown a documented safety record and very high bioavailability at several doses given intravenously with very few adverse reactions.

Its mode of action is unique and its classification is a defense-imetic antibiotic with strong anti-inflammatory properties and antiviral properties.

I urge you as a Pfizer investor to look into a possible partnership or directorship of the development of this novel and effective antiviral agent with potent anti-inflammatory properties which will not only help millions of people across the world but also offer great potential value to the Pfizer Corporation.
Pfizer with its world class resources is in a unique position to be a global leader in the successful battle against SARS and Covid 19 and I hope you have already made contact with the company !!

Here is the contact link for reaching out to the CEO Leo Erlich covid19@ipharminc.com

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent IPIX News